ABSTRACT

The current work enumerates all developed analytical methods for the estimation of the combination of Lumacaftor and Ivacaftor in pharmaceutical dosage forms, used for the treatment of cystic fibrosis. Cystic Fibrosis is a multi-organ disorder caused by dysfunctional CFTR gene mutations. It mostly arises in the lungs but also impacts some body parts such as the colon, liver, kidneys, and pancreas. The CFTR protein mutation leads to impaired transport of fluid, Bicarbonate, Na+ & Cl- ions, leading to the thickening of mucus on the cell membrane and cellular damage. Most researchers have done their work on Lumacaftor and Ivacaftor regarding Pharmacology, Mode of Action, and Synthesis but in the present work, we have focused on different types of analytical techniques used to determine the Lumacaftor and Ivacaftor in pharmaceutical dosage form. We have reviewed various analytical methods, such as HPLC, RP-HPLC, UP-HPLC, and LC-MS techniques that have been developed for the combination of Lumacaftor and Ivacaftor. According to the literature, most of the elution was carried out by the Isocratic method using the mobile phase which includes Acetonitrile, water, and buffer. The HPLC method has been the most widely used analytical technique for the past decade. Keywords: Cystic Fibrosis, HPLC, Ivacaftor, LC-MS, Lumacaftor
Publication date: 01/11/2024

https://ijbpas.com/pdf/2024/November/MS_IJBPAS_2024_8391.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.11.8391